Table 2 Possible risk factors for major adverse outcomes among clinical characteristics and serum biomarkers at week 8.
Clinical characteristics | N = 223 | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
MAOs | P | HR | 95% CI | P | ||
Gender | ||||||
Male | 159 (71.3%) | 63 (39.6%) | 0.57 | 1.08 | 0.65–1.85 | 0.76 |
Female | 64 (28.7%) | 25 (39.1%) | 1.00 | |||
Age at diagnosis | ||||||
<17 years | 46 (20.6%) | 19 (41.3%) | 0.83 | 0.99 | 0.56–1.71 | 0.99 |
≥17 years | 177 (79.4%) | 69 (39.0%) | 1.00 | |||
Disease duration | ||||||
<3 years | 75 (33.6%) | 27 (36.0%) | 0.72 | 1.30 | 0.74–2.24 | 0.36 |
≥3 years | 148 (66.4%) | 61 (41.2%) | 1.00 | |||
Disease type | ||||||
Ileitis type | 32 (14.3%) | 11 (34.4%) | 0.64 | 0.89 | 0.37–2.16 | 0.80 |
Ileocolitis type | 159 (71.3%) | 66 (41.5%) | 1.06 | 0.56–2.17 | 0.87 | |
Colitis type | 32 (14.3%) | 11 (34.4%) | 1.00 | |||
Disease behavior | ||||||
Penetrating type | 51 (22.9%) | 27 (52.9%) | 0.02 | 2.16 | 1.14–4.14 | 0.02 |
Stricturing type | 93 (41.7%) | 37 (39.8%) | 1.33 | 0.73–2.48 | 0.36 | |
Inflammatory type | 79 (35.4%) | 24 (30.4%) | 1.00 | |||
Anal lesions | ||||||
Present | 139 (62.3%) | 56 (40.3%) | 0.81 | 0.98 | 0.62–1.59 | 0.94 |
Absent | 84 (37.7%) | 32 (38.1%) | 1.00 | |||
History of smoking | ||||||
Present | 47 (21.1%) | 20 (42.6%) | 0.78 | 1.03 | 0.58–1.78 | 0.91 |
Others | 176 (78.9%) | 68 (38.6%) | 1.00 | |||
Immunosuppressants | ||||||
Present | 40 (17.9%) | 17 (42.5%) | 0.73 | 1.05 | 0.59–1.77 | 0.85 |
Absent | 183 (82.1%) | 71 (38.8%) | 1.00 | |||
CRP at week 8 | ||||||
≥0.5 mg/dL | 35 (15.7%) | 19 (45.7%) | <0.01 | 2.06 | 1.15–3.55 | 0.02 |
<0.5 mg/dL | 188 (84.3%) | 69 (36.7%) | 1.00 | |||
Alb at week 8 | ||||||
<3.8 g/dL | 54 (24.2%) | 31 (57.4%) | <0.01 | 2.08 | 1.27–3.37 | <0.01 |
≥3.8 g/dL | 169 (75.8%) | 57 (33.7%) | 1.00 | |||
